American Century Companies Inc. Buys 24,153 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI)

American Century Companies Inc. raised its position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) by 44.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 78,143 shares of the company’s stock after buying an additional 24,153 shares during the quarter. American Century Companies Inc. owned 0.10% of Trevi Therapeutics worth $322,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the business. Geode Capital Management LLC raised its stake in Trevi Therapeutics by 10.2% during the third quarter. Geode Capital Management LLC now owns 1,264,166 shares of the company’s stock worth $4,223,000 after acquiring an additional 117,418 shares in the last quarter. Rosalind Advisors Inc. boosted its holdings in shares of Trevi Therapeutics by 41.7% during the 4th quarter. Rosalind Advisors Inc. now owns 1,062,500 shares of the company’s stock worth $4,378,000 after buying an additional 312,500 shares in the last quarter. State Street Corp grew its position in shares of Trevi Therapeutics by 5.9% during the 3rd quarter. State Street Corp now owns 952,912 shares of the company’s stock worth $3,183,000 after buying an additional 53,051 shares during the period. Charles Schwab Investment Management Inc. lifted its position in shares of Trevi Therapeutics by 14.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 173,063 shares of the company’s stock valued at $713,000 after acquiring an additional 22,145 shares during the period. Finally, Bank of New York Mellon Corp boosted its holdings in Trevi Therapeutics by 2.1% in the fourth quarter. Bank of New York Mellon Corp now owns 140,219 shares of the company’s stock worth $578,000 after acquiring an additional 2,935 shares in the last quarter. 95.76% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, CEO Jennifer L. Good sold 5,263 shares of the business’s stock in a transaction that occurred on Friday, March 21st. The stock was sold at an average price of $6.58, for a total value of $34,630.54. Following the completion of the sale, the chief executive officer now owns 213,313 shares in the company, valued at approximately $1,403,599.54. The trade was a 2.41 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Farrell Simon sold 81,313 shares of the firm’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $6.75, for a total transaction of $548,862.75. Following the transaction, the insider now directly owns 76,900 shares in the company, valued at $519,075. This trade represents a 51.39 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 24.37% of the company’s stock.

Trevi Therapeutics Trading Up 5.3 %

NASDAQ:TRVI opened at $5.56 on Monday. Trevi Therapeutics, Inc. has a 12 month low of $2.30 and a 12 month high of $7.39. The company has a 50 day simple moving average of $5.30 and a two-hundred day simple moving average of $4.08. The company has a market cap of $537.55 million, a PE ratio of -12.64 and a beta of 0.41.

Trevi Therapeutics (NASDAQ:TRVI) last announced its quarterly earnings data on Tuesday, March 18th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.01. Research analysts forecast that Trevi Therapeutics, Inc. will post -0.49 earnings per share for the current year.

Analysts Set New Price Targets

TRVI has been the subject of several analyst reports. D. Boral Capital reiterated a “buy” rating and issued a $21.00 target price on shares of Trevi Therapeutics in a report on Wednesday, March 19th. Raymond James raised shares of Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and boosted their target price for the company from $9.00 to $29.00 in a report on Monday, March 10th. Needham & Company LLC reaffirmed a “buy” rating and issued a $24.00 price target on shares of Trevi Therapeutics in a report on Tuesday, April 8th. Oppenheimer lifted their target price on shares of Trevi Therapeutics from $12.00 to $20.00 and gave the company an “outperform” rating in a research report on Tuesday, March 11th. Finally, HC Wainwright restated a “buy” rating and issued a $12.50 target price on shares of Trevi Therapeutics in a research report on Wednesday, March 19th. Seven research analysts have rated the stock with a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $17.56.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.